CHICAGO - A novel MRI-guided procedure that uses therapeutic ultrasound effectively treats prostate cancer with minimal side effects, according to a new study presented today at the annual meeting of the Radiological Society of North America (RSNA). Researchers said the incision-free technique could also be used to treat benign enlargement of the prostate gland.
Prostate cancer is the second-leading cause of cancer death in men after lung cancer. Treating disease in the small gland that surrounds the urethra just outside the bladder is challenging. Surgery and radiation are not always effective and can result in incontinence, impotence and bowel dysfunction. Other currently available techniques lack sophisticated imaging guidance and temperature monitoring.
In recent years, a minimally invasive method called MRI-guided transurethral ultrasound ablation (TULSA) has emerged as a promising treatment option. TULSA works by delivering precise doses of sound waves to diseased prostate tissue while sparing the healthy nerve tissue surrounding the prostate.
TULSA relies on a rod-shaped device that is inserted into the urethra. The novel device has 10 ultrasound-generating elements that can cover the entire prostate gland. One or more of the elements are used to send out sound waves that heat and destroy the target prostate tissue. The elements are controlled automatically by a software algorithm that can adjust the shape, direction and strength of the therapeutic ultrasound beam. The entire procedure takes place in an MRI scanner so that doctors can closely monitor treatment and assess the degree and location of heating.
"Unlike with other ultrasound systems on the market, you can monitor the ultrasound ablation process in real time and get immediate MRI feedback of the thermal dose and efficacy," said study co-author Steven S. Raman, M.D., professor of radiology and urology, and director of Prostate MR Imaging and Interventions and Prostate MR Imaging Research at the University of California at Los Angeles (UCLA). "It's an outpatient procedure with minimal recovery time."
In the new multicenter study, researchers reported on the 12-month outcomes from the TULSA-PRO® ablation clinical trial (TACT). The trial enrolled 115 men, median age 65, with localized low or intermediate risk, gland-confined prostate cancer. Clinicians delivered TULSA treatment to the entire gland. Treatment time averaged 51 minutes.
Prostate volume in the study group decreased on average from 39 cubic centimeters pre-treatment to 3.8 cubic centimeters a year after treatment. Overall, clinically significant cancer was eliminated in 80% of the study participants. Seventy-two out of 111 men, or 65%, had no evidence of any cancer at biopsy after one year. Blood levels of prostate-specific antigen (PSA), a marker of prostate cancer, fell by a median of 95%. There were low rates of severe toxicity and no bowel complications.
"We saw very good results in the patients, with a dramatic reduction of over 90 percent in prostate volume and low rates of impotence with almost no incontinence," Dr. Raman said.
Approved for clinical use in Europe, TULSA has just received FDA 510(k) clearance for prostate tissue ablation in the United States. Assuming follow-up studies support the preliminary results, the technique could develop into an important tool for treating both prostate cancer and benign prostatic hyperplasia, or enlargement of the prostate.
"There are two very unique things about this system," Dr. Raman said. "First, you can control with much more finesse where you're going to treat, preserving continence and sexual function. Second, you can do this for both diffuse and localized prostate cancer and benign diseases, including benign hyperplasia."
TULSA also has the benefit of allowing further treatment if needed, Dr. Raman said. If it fails, then the procedure can be repeated, and more aggressive invasive approaches like surgery and radiation therapy can still be used. Alternatively, TULSA may enable noninvasive treatment for localized radiation failure.
The study also supports the use of MRI for post-treatment monitoring of patients who undergo TULSA. MRI at one year after treatment had a negative predictive value of 93 to 96% for detecting residual cancer, meaning it was very accurate for ruling out disease recurrence in patients.
Recent PROF News
- Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow • GlobeNewswire Inc. • 04/22/2024 08:15:00 PM
- Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference • GlobeNewswire Inc. • 04/09/2024 11:45:00 AM
- Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/07/2024 09:05:00 PM
- Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference • GlobeNewswire Inc. • 03/04/2024 09:30:00 PM
- Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure • GlobeNewswire Inc. • 02/27/2024 12:45:00 PM
- Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow • GlobeNewswire Inc. • 02/15/2024 09:30:00 PM
- Profound Medical Announces Non-Brokered Private Placement • GlobeNewswire Inc. • 01/16/2024 09:30:00 PM
- Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenues • GlobeNewswire Inc. • 01/03/2024 09:15:00 PM
- Profound Medical Announces Pricing of US$20 Million Public Offering of Common Shares • GlobeNewswire Inc. • 12/28/2023 03:40:00 AM
- Profound Medical Announces Proposed Public Offering of Common Shares • GlobeNewswire Inc. • 12/27/2023 09:15:00 PM
- Profound Medical to Participate in the Stifel 2023 Healthcare Conference • GlobeNewswire Inc. • 11/08/2023 12:45:00 PM
- Profound Medical Announces CMS Extension of Temporary ‘Code’ for TULSA to ASC Setting • GlobeNewswire Inc. • 11/03/2023 12:00:00 PM
- Profound Medical Announces Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/02/2023 08:05:00 PM
- Profound Medical to Release Third Quarter 2023 Financial Results on November 2 – Conference Call to Follow • GlobeNewswire Inc. • 10/19/2023 08:30:00 PM
- Profound Medical 2023 Virtual Analyst & Investor Day Agenda • GlobeNewswire Inc. • 10/10/2023 08:30:00 PM
- Profound Medical Receives U.S. FDA 510(k) Clearance for TULSA-PRO® Thermal Boost • GlobeNewswire Inc. • 09/25/2023 08:05:00 PM
- Save the Date: Profound Medical to Host Virtual Analyst & Investor Day on October 13 • GlobeNewswire Inc. • 09/21/2023 12:00:00 PM
- Profound Medical to Participate in the 2023 Cantor Global Healthcare Conference • GlobeNewswire Inc. • 09/19/2023 08:45:00 PM
- Profound Medical Announces At-the-Market Offering of up to US$30,000,000 • GlobeNewswire Inc. • 09/06/2023 11:23:52 PM
- Profound Medical Announces Second Quarter 2023 Financial Results • GlobeNewswire Inc. • 08/09/2023 08:05:00 PM
- Profound Medical to Release Second Quarter 2023 Financial Results on August 9 – Conference Call to Follow • GlobeNewswire Inc. • 08/02/2023 08:30:00 PM
- Profound Medical Announces New CPT® Category 1 Codes from the AMA for TULSA to Treat Prostate Diseases • GlobeNewswire Inc. • 06/02/2023 05:40:00 PM
- Profound Medical Announces Upcoming Investor Events • GlobeNewswire Inc. • 05/30/2023 12:00:00 PM
- Profound Medical to Participate in A.G.P.’s Virtual Healthcare Conference • GlobeNewswire Inc. • 05/18/2023 12:00:00 PM
- Profound Medical Annual and Special Meeting of Shareholders Voting Results • GlobeNewswire Inc. • 05/17/2023 08:15:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM